TickerFacts.

Alpha Cognition Inc. (ACOG): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$20.67M
Year ended 2025-12-31
-$31.18M
Trailing 12 months to 2026-06-30
2024-12-31: -$7.78M2025-12-31: -$20.67M-$20.67M
2024-12-31 Free Cash Flow (USD) 2025-12-31
Period endedFree Cash FlowChange YoYSource filing
2025-12-31-$20.67Mn/m2026-03-31, From 2025-01-01
2024-12-31-$7.78Mn/a2026-03-31, From 2024-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedFree Cash FlowChange YoY
Alpha Cognition Inc. (ACOG)2025-12-31-$20.67Mn/m
TScan Therapeutics, Inc. (TCRX)2025-12-31-$139.73Mn/m
Taysha Gene Therapies, Inc. (TSHA)2025-12-31-$93.83Mn/m
Caribou Biosciences, Inc. (CRBU)2025-12-31-$112.35Mn/m
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31-$19.44Mn/m
Relay Therapeutics, Inc. (RLAY)2025-12-31-$235.87Mn/m
Fate Therapeutics Inc (FATE)2025-12-31-$112.04Mn/m
Pelthos Therapeutics Inc. (PTHS)2025-12-31-$22.69Mn/m
DBV Technologies S.A. (DBVT)2025-12-31-$121.71Mn/m

Compare ACOG, TCRX, TSHA, CRBU side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗